Radiotherapy that is adapted for the severity of disease and followed by a shortened course of chemotherapy substantially improves the outcome of children with a type of brain tumour called medulloblastoma, claim investigators in an Online/Article in The Lancet Oncology.
"Not only can we now cure about 70% of children with high-risk medulloblastoma, we can also cure more than 80% of those with standard-risk disease with a shorter, and therefore more convenient, chemotherapy approach", notes author Dr Amar Gajjar from St Jude's Children's Research Hospital in Memphis, USA.
In their study, the researchers administered adjusted the doses of radiotherapy given to 134 children with medulloblastoma, depending on how severe their disease was. Children were classified as being either at standard risk if they had only small tumours remaining after surgery and no evidence that the disease had spread to the rest of the body, or at high risk if they had larger tumours, or evidence of spread to other organs. Children in the high risk group were given a higher dose of radiotherapy to the neck and spine than were those in the standard-risk group, but both groups received an additional boost of radiation to the actual site of the tumour, a shortened course of chemotherapy, and a reinfusion of bone-marrow stem cells after each cycle of chemotherapy.